Impaired healing in diabetes affects the resolution of both acute and chronic wounds. The vicious circle between wound chronicity and a deficient control of local infection is the cause that diabetic patients constitute 85% of all non-traumatic lower extremity amputations. From an etiological viewpoint, hyperglycemia is what triggers the onset and progression of biochemical disturbances that lead to systemic complications. In contrast to normal wound healing, physiological apoptotic clearance of inflammatory cells is prevented and the inflammatory phase is abnormally prolonged in diabetic wounds. Pro-inflammatory cytokines as tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) are increased in diabetic wounds with negative local and remote consequences. The etiopathogenic network consisting of inflammatory cytokines, local proteases, reactive oxygen and nitrogen species produces a cytotoxic and pro-degradation environment within the wound bed that impairs granulation and re-epithelialization. The non-enzymatic glycation of proteins, generating advanced glycation end-products (AGE), acts as an active pathogenic stream affecting healing. The accumulation of AGE interferes with DNA replication, cell anchoring, migration and proliferation. The binding of AGE to a receptor model (RAGE) may completely hamper the healing process. Diabetes affects the recruitment and differentiation of bone marrow-derived stem cells, thereby limiting the availability of tissue repair cells. Re-epithelialization is also hindered by incomplete activation and/or differentiation of keratinocytes that impair migration. Novel and revolutionary pharmacological interventions are urgently needed to reduce diabetes complications, such as amputations of the lower extremities.

Keywords: diabetes, ulcer, amputation, granulation, re-epithelialization

Biotecnología Aplicada 2010;27:255-261

ABSTRACT

Particularidades celulares y moleculares del mecanismo de cicatrización en la diabetes. El deterioro de la cicatrización en la diabetes afecta la resolución tanto de heridas agudas como crónicas. Se establece un circulo vicioso interamplificativo entre el fenotipo crónico y el control deficiente de la infección, que determina que el 85% de todas las amputaciones no traumáticas de miembros inferiores se practiquen en individuos diabéticos. La hiperglycemia es el detonador etiopatogénico proximal en el inicio y progresión de los desórdenes bioquímicos que dan lugar a las complicaciones sistémicas. Contrario a lo que ocurre durante la cicatrización normal, la eliminación apoptótica fisiológica de las células inflamatorias se detiene, lo que provoca un anormal estancamiento de la fase inflamatoria en las heridas diabéticas. En estas, además existe una sobre-expresión de citocinas pro-inflamatorias como el factor de necrosis tumoral alfa (del inglés, TNF-α) y la interleucina-1β (IL-1β), lo que trae consigo consecuencias deletéreas de impacto local y remoto. La red etiopatogénica de citocinas inflamatorias, proteasas locales, especies reactivas al nitrógeno y al oxígeno, propician un ambiente citotóxico y pro-degradativo en el lecho de la herida, que perjudica la granulación y re-epitelización. La glicosilación no enzimática de proteínas persiste como un ingrediente patogénico activo en el deterioro del proceso de cicatrización. La acumulación anormal de productos glicosilados interfere con la replicación del ADN, el anclaje, la migración y la proliferación celular. La diabetes afecta la liberación, el reclutamiento y la diferenciación de las células madre derivadas de médula ósea, lo que limita la disponibilidad de estas células para reparar el tejido. La re-epitelización también se altera debido a la activación y/o diferenciación incompleta de los queratinocitos, lo cual obstruye su migración. Se necesitan de forma urgente abordajes farmacológicos novedosos y revolucionarios para reducir las diversas complicaciones de la diabetes, tales como la temida amputación de miembros inferiores.

Palabras clave: diabetes, úlcera, amputación, granulación, re-epitelización

Introduction

Amputations are often considered to be the beginning of the end for patients with diabetes, since lower extremity ulceration is one of the several serious long-term complications associated to DM. The deficient healing of soft peripheral tissues leads to the onset of lower extremity ulcerations [1-3].

The term “diabetic foot” defines the specific features of the feet of diabetic patients, differentiating it from other conditions affecting the lower extremities. Infection, ulceration and the destruction of deep tissues associated with neurological abnormalities and diverse degrees of peripheral vascular disease at the lower limbs define diabetic foot [4]. Although both neuropathy and vasculopathy, as individual entities, may co-exist and interact in diabetic foot, substantial clinical and histological differences can be distinguished between neuropathic and ischemic ulcer beds. Thus, neuropathy and hypo-perfusion of lower extremity tissues are long-term complications of hyperglycemia, which together with wound size and the host’s inability to fight local infection, determine the prognosis and the outcome.

Throughout evolution, wound healing has been a mechanism favoring the urgent structural and functional restoration of an injured area; it occurs as an innate cellular response to injury by involving two major cell functions: (1) the response of tissue-promoting cells and (2) the transient infiltration and homing of inflammatory cells. Diabetic wounds are a therapeutic challenge since we are dealing with the gross clinical expression of an enormous array of biochemical disturbances that have progressively undermined elementary biological mechanisms.

Here we examine the current knowledge of the biology of diabetic wounds, particularly the pro-inflammatory arm and the toxicity produced by the burden of the accumulation of advanced glycation end-products (AGE), leading to the onset of the hard-to-heal phenotype. The data here shown was selected from 910 reviewed papers downloaded from Pubmed and Bioline International (www.bioline.org.br) data bases through a direct search or through the Reference Manager program. Articles were retrieved using the following key restriction criteria: (1) Diabetic ulcer + inflammatory infiltrate, (2) Diabetic ulcer + granulation tissue, (3) Diabetic ulcer + epithelialization, (4) Diabetic ulcer + AGE, (5) Diabetes + RAGE + complications, (6) Diabetic ulcer + angiogenesis, and (6) Diabetic ulcer + growth factors.

**Glucotoxicity**

Although the onset and magnitude of diabetes complications are largely influenced by individual genetic factors, hyperglycemia is what triggers the cascade of complications [5]. The difficulty in initiating and/or sustaining a physiological repair mechanism is one of the worst complications [6] since diabetes impairs most, if not all, of the events involved in the healing process (Table). The ulcer healing process is further complicated when lower limb hypoxia is added to the long-term hyperglycemia-derived toxicity [7]. Chronic glucotoxicity affects most of the economy cells including those involved in the repair mechanism as shown by in vitro and in vivo studies under short-term or long-term exposure. Glucose toxicity is associated but not limited to: an increasing level of superoxide anions, impaired nitric oxide (NO) synthesis and subsequent depletion, the inhibition of protective and self-defense mechanisms of cells, the induction of DNA damage and distribution abnormalities [8]. A general expression of this toxic effect is the resistance of cells to divide. The high level of glucose stops the production of endothelial and fibroblastoid cells; although the pathways leading to cell cycle arrest may differ between lineages [9], a common toxic effector appears to be the generation of reactive oxygen species [10]. Glucose overload has been proven to inhibit endothelial nitric oxide synthase activity by mitochondrial superoxide production, it also imposes a pro-inflammatory program which may amplify insulin resistance and favor the onset of a chronic inflammatory response phenotype [11, 12]. As later shown, the systemic pro-inflammatory environment favors insulin resistance and often leads to more toxicity through hyperinsulinemia, forming a toxic vicious circle. The glucotoxicity-derived loops of oxidative stress, pro-inflammation, and the accumulation of terminal glycation products (commonly known as AGE - from advanced glycation end-products), disrupts the local homeostasis and depletes the wound cells of antioxidant defense resources and of growth factors and their receptors.

**The inflammatory environment in the diabetic wound**

A chronic diabetic wound must be considered a pro-inflammatory organ placed in a metabolically deregulated host. The pool of wound-derived cytokines is enriched in the central circulation and blocks the action of insulin by phosphorylating key substrate proteins [13].

Tissue injury causes the immediate onset of acute inflammation. The inflammatory response is characterized by patterns of several leukocyte subsets that change in space and time and the well-defined chronology of the response is essential for optimal repair [14]. The diabetic wound does not show the orderly cascade of events that characterizes normal wound healing; in contrast, the inflammatory reaction in diabetic wounds is prolonged. Serial biopsies from both neuropathic and ischemic ulcers-derived granulation tissue have indicated important histological differences, and therefore interpretative differences, between them in the absence of infection. The infiltration of neutrophils is intense, prolonged and not topographically polarized particularly in neuropathic wounds. It is not uncommon to observe a chronic inflammation preceded by an “acute” inflammatory cell, co-existing with a poor accumulation of extra-cellular matrix (ECM) in which collagen deposit is poor. In contrast, a widespread infiltration of round cells prevail.

**Table 1. General characteristics of diabetic chronic wounds**

<table>
<thead>
<tr>
<th>Wound phase</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemostasis</td>
<td>Ordinarily shifted to a pro-coagulant state. Fibrinolysis is impaired leading to macroscopic plugging.</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Ordinarily protracted in both acute and chronic stages. Intense infiltration of neutrophils or mononuclear cells.</td>
</tr>
<tr>
<td>Granulation</td>
<td>Fibroblasts and fibrocytes chemotaxis to the wound is reduced. Fibroblasts and vascular cells replication is delayed or failed. Arrest and undue apoptosis prevalent. Reduced secretion of extracellular matrix and impaired cellular anchoring.</td>
</tr>
<tr>
<td>Tissue formation</td>
<td>Late or poor collagenization with reduced tensile resistance. Reduced myofibroblast population and poor contraction. Angiogenic response is severely impaired in diabetic wounds.</td>
</tr>
<tr>
<td>Re-epithelization</td>
<td>Appears ordinarily delayed leading to chronicity. Epithelial migration is likely impaired. Normal keratinocytes differentiation is impaired.</td>
</tr>
<tr>
<td>Remodeling</td>
<td>It is a slow process ordinarily affected by in-situ re- ulceration.</td>
</tr>
</tbody>
</table>

in patients suffering from bed wound ischemia. These observations lead to the conclusion that the bioche-
microenvironment in ischemic and neuropathic ulcers is different and that the inflammatory “badge”
corresponds to the most prevalent pathogenic compo-
nent of the wound [15].

Although chronic diabetic ulcer is installed during the
inflammatory phase of the normal healing process,
this inflammatory reaction does not necessarily imply a
local physiological control of bacteria. Experimental
studies have shown that macrophages from diabetic mice phagocyte the cell detritus at a much slower rate and
much less efficiently than their non-diabetic coun-
terparts [15]. Diabetic individuals are more suscepti-
ble to both wound infection and hyper-in-
terpret their results to the increa-
sed levels of pro-inflammatory cytokines as tum-
or necrosis factor α (TNF-α) and interleukin 6 (IL-6)
[16]. Immune-related diabetes seems to occur because
high glucose concentrations substantially disturb cell-
dependent responses, whereas the correction of hyper-
glycemia improves leukocyte chemotaxis [17].

Pro-inflammatory cytokines are strongly up-regula-
ted during the inflammatory phase. Data derived from
diabetic rodents have shown a deregulated expres-
sion of macrophage inflammatory protein-2 (MIP-2)
and macrophage chemoattractant protein-1 (MCP-1)
which is associated with the increased and protracted
infiltration of both neutrophils and macrophages into
the wound [18]. Compelling evidence indicates that
neutrophils are critical for the acquisition of a pro-
degradative phenotype resulting from the imbalance
between matrix synthesis and the degradation by sti-
mulating the synthesis of matrix metalloproteinases
(MMPs) [19]. In line with this, TNF-α and interleu-
kin 1β (IL-1β) secreted by neutrophils trigger signals
for MMPs expression via the nuclear factor kappa B
(NFkB) common pathway. Within the context of the
wound, molecular targets of MMPs are numerous, and
include not only elements of the ECM, but also locally
secreted growth factors and their receptors. The ob-
seration that diabetic wounds are enriched in MMPs
support the assumption that impaired growth factor
availability may limit healing [18, 20, 21]. Prolonged
neutrophils infiltration is also linked to the overpro-
duction within the wound area of elastase, reactive
oxygen species (ROS) and reactive nitrogen species
(RNS); all with a remarkable cytotoxic and pro-degra-
dative potential [22, 23]. In fact, high circulating and
neutrophil-associated elastase levels are attributable
to a poor glycemic control and are currently consid-
ered as risk markers for the development of diabetic
angiopathy [24]. Fibronection degradation for instance,
is referred as one of the several causes of diabetic re-
epithelialization failure because epidermal keratino-
cytes require the interaction between fibronectin and
its surface receptor integrin α5β1 to effectively migra-
tate [25]. Curiously, insulin-degrading activity has also
been demonstrated in the fluid of diabetic wounds
which have been shown to correlate with the glycated
hemoglobin levels. This evidence again highlights the
importance of a strong metabolic control to ensure a
linear healing process [26].

In contrast to the increased MMP-8 and 9 displayed
by the non-healing diabetic wound, the concentration
of NO is significantly reduced. Diabetic skin fibro-
basts treated with NO donor compounds increased
cell proliferation, and decreased the expression of
MMP-8 and 9 in a dose-dependent manner. Thus, the
fact that NO resums the cell proliferation program
and promotes the re-establishment of an blood vessel
effect is an argument in favor of beneficial effect of
NO in wound healing [20].

An explanation for the abnormal diabetic pro-in-
flammatory reaction suggests that inflammatory cells
evade apoptosis and thus extend the wound bed ho-
ing in a non-physiological manner. Although certain
forces seem to prevent apoptosis of the inflammatory
cells, other cells that are essential in granulation tis-
sue growth are extremely prone to committing suicide
[27]. TNF-α has been largely involved in this con-
troversial event. In addition to MMPs, high levels of
TNF-α in the wound have been identified as a pro-
ductive molecular factor for wound closure failure
[18]. Type 2 diabetes is associated with high serum
levels of inflammatory cytokines such as TNF-α
[28]. Within the wound context, TNF-α stimulates its
own secretion and that of IL-1β, which contributes
to a persistent inflammatory status [29] pushing the
wound toward a catabolic scope [30]. In line with this,
TNF-α application causes a decrease in the tensile
strength of the wound by reducing the expression of
collagen types I and III [31, 32]. In general, there is
a sharp antagonism between the pro-synthetic role of
transforming growth factor β1 (TGF-β1) and the oppo-
site TNF-α effect in terms of ECM deposition, wound
contraction and maturation. The latter, through the
-675

-257

-225

-325

-515

-530

-621

-295

-325

-325

-425

-430

-467

-481

-481

-502

-509

-530

-537

-544

-565

-575

-593

-598

-625

-628

-642

-677

-747

-747

-747

-747

-747

-747

-747

-747

-747

-747

-747

-747

-747

-747
also been involved in the pathogenesis of micro and macrovascular pathologies [37]. Thus, the high level of fibroblastic cell apoptosis is a meaningful contributing factor for a deficient healing response in diabetic individuals. It is also likely that the TNF-mediated insulin-resistance in the wounded tissue cells [38] could behave as a pro-apoptotic factor. Accordingly, an anti-TNF-α neutralizing intervention restored insulin sensitivity and improved the healing process [39].

As shown by in silico simulation methods, any therapeutic approach aimed toward neutralizing TNF-α, or increasing active TGF-β1, would be similarly effective regardless of the initial assumption of the underlying disarrangement in the ulcerogenic process [40].

Chronic wounds, and especially diabetic foot ulcers, have a highly pro-oxidant microenvironment which complements and amplifies the pro-inflammatory arm in the cytotoxic cascade. Diabetic tissues produce abnormal amounts of ROS and are, at the same time, the victims of their attack. In a systemic context, ROS contribute to the onset of insulin resistance by inactivating the signaling pathway between the insulin receptor and the glucose transporter system [41]. Leukocytes, especially neutrophils are a rich source of various reactive species which are released into the wound environment. Endothelial cells and fibroblasts, particularly senescent fibroblasts, are a prominent population in chronic wounds, but also a potential source of ROS. Thus, the disturbed oxidant/antioxidant balance within the chronic wound is considered a major factor in the amplification of the inflammatory state [42] in regard to the deficient availability of growth factors and functionality [43]. Conclusively, TNF-α inhibition is apparently sufficient to neutralize the misbehaving inflammatory machinery in non-healing wounds, so as to assist in reprogramming the whole local microenvironment.

The cytotoxic effect of the AGE

Mounting evidence indicates that the biology of the AGE-RAGE system in diabetic individuals is a molecular trigger and amplifier of most, if not all, of the accumulative disease complications, including impaired healing [44]. Within Brownlee’s “Unifying Hypothesis” AGE are in second place within the apparently distant pathogenic pieces. Hyperglycemia seems to be a major requirement in the non-enzymatic glycation process that generates the heterogeneous group of cytotoxic AGE compounds. Consequently, ROS are formed along with the AGE generation process, and correspondingly, ROS hasten AGE formation, thus paving the way for a self-perpetuating pathogenic cycle of ROS-AGE which appears to characterize the biochemistry of diabetes [45-47]. The accumulation of AGE in cells exposed to chronic hyperglycemia and oxidative stress result in irreversible damages even when these cells return to a normal glycemic environment [45, 46, 48-52].

AGE acts through a cell surface receptor that coincidentally appears to be up-regulated in most tissues of diabetic patients. Different receptors for AGE have been discovered, one of these, termed RAGE (Receptor for Advanced Glycation End-Products), initiates the intracellular signaling that disrupts cellular function. Nuclear factor kappa-B (NF-κB) binding sites, an interferon-γ response element, and a nuclear factor-interleukin-6 DNA binding motif, are located on the RAGE promoter region. The fact that NF-κB controls the cellular expression of RAGE establishes a functional link between RAGE and the inflammatory response [53, 54].

AGE-RAGE interaction triggers the generation of pro-inflammatory cytokines, adhesion molecules, and chemokines, thus enhancing the attraction of more inflammatory cells? and perpetuating the inflammatory profile [55]. Up-regulation of RAGE has been described on endothelial, smooth muscle cells and mononuclear phagocytes; while AGE tends to accumulate in non-labile dermal connective tissues like collagen and elastin, thus meaning that the skin of diabetics is physicochemically altered. Under the microscope, diabetic skin have degenerative changes observed as loosely arranged collagen and increased apoptotic cells. The immunohistochemical analysis of the granulation tissue of the diabetic patients [58]. This demonstrates the deleterious involvement of MGO-AGE-RAGE in diabetic tissue damage [59]. Other experiments show that diet-derived AGE acts through a cell surface receptor that coin- 

38. Mantzaros CS, Moschos S, Aravou- 
40. Mi Q, Riviere B, Clermont G, Steed DL, Vodovotz Y. Agent-based model of inflam- 
41. Brownlee M. Biochemistry and mole- 
42. Weiss SJ. Tissue destruction by neutro- 
45. Brownlee M. Biochemistry and mole- 
46. Biotecnología Aplicada 2010; Vol.27, No.4
activation of p38 and JNK pathways, leading to an enhanced caspase-3 activity and FOXO1 transcription factor [64]. This and other evidence currently place the AGE-RAGE axis at the center of the toxic and pro-inflammatory cascade of events that disturbs wound healing in diabetes [65]. In summary, AGE-RAGE interaction is so deleterious that it facilitates the onset of pro-apoptotic, pro-inflammatory, pro-oxidant and pro-degradative wound environment.

Granulation and re-epithelialization processes are impaired in diabetes
It is known that diabetes is accompanied by the delayed and/or insufficient production of granulation tissue. Findings show that diabetic ulcer fibroblasts are morphologically different from their healthy counterparts. Diabetic fibroblasts are larger and widely spread. Under transmission electron microscopy these cells reveal a large dilated endoplasmic reticulum, a lack of microtubular structures and multiple lamellar vesicles. This abnormal morphology provides the theoretical basis for a decreased proliferative capacity and other abnormal traits [66, 67]. It has not been established if these structural changes are secondary to a long-term exposure to hyperglycemia and the general cytotoxic milieu. But it has been historically well-documented that high glucose concentrations inhibit fibroblast proliferation and induces growth factor resistance, which tend to explain their proliferative failure. We have detected an enhanced expression of the anti-proliferative, pro-senescent protein [68], pro-histin in granulation tissue fibroblasts of diabetic foot ulcers as compared with their healthy subjects repairing a second degree burn (Jorge Berlanga, unpublished). Thus, it is accepted that fibroblasts derived from chronic diabetic ulcers have lower intrinsic proliferative capability than those collected from intact skin areas [69]. To further substantiate this assertion, it has been shown that cultured fibroblasts from diabetic patients require the presence of multiple supplements in addition to growth factors for their proliferation while other data suggest a deficit of certain growth factors receptors involved in cell proliferation [70]. Dermal fibroblasts from diabetic mice exhibit abnormalities even when grown in an *ex vivo* culture environment that has been optimized for nutrients, growth factors, and glucose concentrations. Different *in vitro* assays, including hypoxic or normoxic conditions, show that the diabetic fibroblast population does not physiologically migrate as does its healthy counterpart, and thus becomes hyporesponsive to the hypoxic challenge [71, 72]. These cells are also more prone to ischemia-induced apoptosis and to *up-regulate* p53 expression than the non-diabetic controls. They are also unable to *up-regulate* the Vascular Endothelial Growth Factor (VEGF) production under hypoxic conditions whereas wild-type fibroblasts show a several fold increase of VEGF under the same stressing conditions [73].

Under hypoxic conditions, Hypoxia Inducible Factor-1α (HIF-1α) is stabilized against degradation and under-regulates a series of genes involved in angiogenesis, glycocalyx metabolism, cell proliferation, and survival. Studies have shown that HIF-1α protein levels are dramatically reduced in wounds from diabetic mice as compared to their non-diabetic littermates [74-76]. Hyperglycemia impairs the hypoxia-dependent stabilization of HIF-1α against proteasomal degradation in primary human dermal fibroblasts, human microendothelial cells, as found in foot ulcer-derived cells [77]. It has been determined that this HIF-1α reduction factor decreases DNA-binding activity and a reduced expression of several downstream target genes, including VEGF. Conversely, the induction of a sustained HIF-1α expression significantly restored the wound healing process [78]. The fibrocyte, a bone marrow-derived mesenchymal progenitor cell appears to contribute to the healing process by enriching the population of fibroblasts and myofibroblasts [79]. Laboratory evidence [80, 81] leads to the hypothesis that fibrocyte wound recruitment and differentiation is reduced in diabetes, acting as a limiting factor for successful and progressive granulation.

Re-epithelialization in mammals is far more complex and much slower than in lower organisms, and demands the combined action of multiple factors for keratinocyte migration and proliferation. Although re-epithelialization failure has been largely recognized as an essential feature of diabetes and other chronic wounds, its molecular basis must still be fully elucidated. All pathologists distinguish the epidermis of a chronic wound edge as a thick and hyperproliferative structure with mitotically active keratinocytes that are apparently unable to migrate along the surface. It has therefore been speculated that the non-healing edge keratinocytes do not successfully complete either of two possible pathways: activation or differentiation [82]. In consonance with this, one of the main issues in chronic wound treatment is how to revert the keratinocytes phenotype into a proper differentiating and migratory program [82].

The first scientific indication that insulin is biologically relevant for skin cells derives from the fact that insulin is an essential component for human keratinocyte culture, demonstrating its involvement in the regulation of proliferation, apoptosis, and metabolism [83, 84]. Recent studies in this field show that insulin contributes to the release of VEGF in skin wound cells through an Akt1-mediated post-transcriptional mechanism [85]. Glucose is known to affect insulin action by regulating the expression of several genes including the insulin receptor at both the transcriptional and translational levels [86]. The lack of an insulin receptor expression results in reduced skin proliferation and abnormal differentiation *in vivo* [87]. Furthermore, glucose has been shown to have a direct toxic effect on keratinocytes. As for other cells grown in the presence of high glucose concentrations, human epidermal keratinocytes significantly reduce proliferation rate and replicating life span [88] and were found to be more susceptible to apoptosis [89]. Other studies also demonstrated that hyperglycemic conditions abrogate the proliferative ability of keratinocytes and their migratory response [90]. Aside from the glucose-mediated direct cytotoxic effect on the keratinocytes, the modification through AGE of type-1 collagen and other ECM proteins impairs the integrin-mediated adhesion of keratinocytes to the basement matrix, and could thus contribute to the pathogenesis of diabetic re-epithelialization failure [91].

47. Yao D, Brownlee M. Hyperglycemia-induced oxidative stress reduces expression of the receptor for advanced glycation and products (RAGE) and RAGE ligands in human microvascular cells. Diabetes 2005;54(9):249-55.
48. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;5:1184-95.
52. Yamagishi S, Matsui T. Smooth muscle cells are morphologically different from their healthy counterparts. Diabetic ulcer fibroblasts as compared with healthy subjects repairing a second degree burn (Jorge Berlanga, unpublished). Thus, it is accepted that fibroblasts derived from chronic diabetic ulcers have lower intrinsic proliferative capability than those collected from intact skin areas [69]. To further substantiate this assertion, it has been shown that cultured fibroblasts from diabetic patients require the presence of multiple supplements in addition to growth factors for their proliferation while other data suggest a deficit of certain growth factors receptors involved in cell proliferation [70]. Dermal fibroblasts from diabetic mice exhibit abnormalities even when grown in an *ex vivo* culture environment that has been optimized for nutrients, growth factors, and glucose concentrations. Different *in vitro* assays, including hypoxic or normoxic conditions, show that the diabetic fibroblast population does not physiologically migrate as does its healthy counterpart, and thus becomes hyporesponsive to the hypoxic challenge [71, 72]. These cells are also more prone to ischemia-induced apoptosis and to *up-regulate* p53 expression than the non-diabetic controls. They are also unable to *up-regulate* the Vascular Endothelial Growth Factor (VEGF) production under hypoxic conditions whereas wild-type fibroblasts show a several fold increase of VEGF under the same stressing conditions [73].

Under hypoxic conditions, Hypoxia Inducible Factor-1α (HIF-1α) is stabilized against degradation and under-regulates a series of genes involved in angiogenesis, glycocalyx metabolism, cell proliferation, and survival. Studies have shown that HIF-1α protein levels are dramatically reduced in wounds from diabetic mice as compared to their non-diabetic littermates [74-76]. Hyperglycemia impairs the hypoxia-dependent stabilization of HIF-1α against proteasomal degradation in primary human dermal fibroblasts, human microendothelial cells, as found in foot ulcer-derived cells [77]. It has been determined that this HIF-1α reduction factor decreases DNA-binding activity and a reduced expression of several downstream target genes, including VEGF. Conversely, the induction of a sustained HIF-1α expression significantly restored the wound healing process [78]. The fibrocyte, a bone marrow-derived mesenchymal progenitor cell appears to contribute to the healing process by enriching the population of fibroblasts and myofibroblasts [79]. Laboratory evidence [80, 81] leads to the hypothesis that fibrocyte wound recruitment and differentiation is reduced in diabetes, acting as a limiting factor for successful and progressive granulation.

Re-epithelialization in mammals is far more complex and much slower than in lower organisms, and demands the combined action of multiple factors for keratinocyte migration and proliferation. Although re-epithelialization failure has been largely recognized as an essential feature of diabetes and other chronic wounds, its molecular basis must still be fully elucidated. All pathologists distinguish the epidermis of a chronic wound edge as a thick and hyperproliferative structure with mitotically active keratinocytes that are apparently unable to migrate along the surface. It has therefore been speculated that the non-healing edge keratinocytes do not successfully complete either of two possible pathways: activation or differentiation [82]. In consonance with this, one of the main issues in chronic wound treatment is how to revert the keratinocytes phenotype into a proper differentiating and migratory program [82].

The first scientific indication that insulin is biologically relevant for skin cells derives from the fact that insulin is an essential component for human keratinocyte culture, demonstrating its involvement in the regulation of proliferation, apoptosis, and metabolism [83, 84]. Recent studies in this field show that insulin contributes to the release of VEGF in skin wound cells through an Akt1-mediated post-transcriptional mechanism [85]. Glucose is known to affect insulin action by regulating the expression of several genes including the insulin receptor at both the transcriptional and translational levels [86]. The lack of an insulin receptor expression results in reduced skin proliferation and abnormal differentiation *in vivo* [87]. Furthermore, glucose has been shown to have a direct toxic effect on keratinocytes. As for other cells grown in the presence of high glucose concentrations, human epidermal keratinocytes significantly reduce proliferation rate and replicating life span [88] and were found to be more susceptible to apoptosis [89]. Other studies also demonstrated that hyperglycemic conditions abrogate the proliferative ability of keratinocytes and their migratory response [90]. Aside from the glucose-mediated direct cytotoxic effect on the keratinocytes, the modification through AGE of type-1 collagen and other ECM proteins impairs the integrin-mediated adhesion of keratinocytes to the basement matrix, and could thus contribute to the pathogenesis of diabetic re-epithelialization failure [91].
In this context, epithelial–mesenchymal interaction plays a prime role in establishing the profile and order of released factors regulating proliferation and differentiation of keratinocytes [92].

Recent experiments have introduced another line of evidence that favors the roles of c-myc and flt-3 ligand in impairing the migration of epithelial edges, involving mechanisms that may ultimately deplete the pool of epidermal stem cells at the non-healing edge [91]. The routine practice of the sharp debridement of ulcers is a useful procedure for epithelial cells to resume their activation cycle and differentiation program by transforming chronicity to a more acute phenotype [93].

Classic experiments provide illustrative examples of the relevance of the epithelial-mesenchymal actions and on the irreplaceable role of growth factor as a networking bridge [94] in re-epithelialization. Skin-reconstitution studies have shown that bone marrow stromal cells (BMSCs), in addition to dermis-localized preadipocytes and fibroblasts, distinctively promote epidermal regeneration [95]. As diabetes proceeds with a deficient secretion of growth factors and other chemotactic mediators in areas of tissue repair, the recruitment of circulating stromal cells may be reduced, which is an additional blow to the already existing high glucose-associated toxicity [96]. Finally, TNF-α has also been involved in epithelial cell arrest by deeply perturbing critical elements of keratinocyte physiology [97].

**Concluding remarks and outlook**

Diabetes complications have a Malthusian behavior because of their unrivaled proportions in terms of morbidity and mortality. Even with optimal management, many individuals with diabetes become blind, develop renal failure and require amputation. The latter is the consequence of the long-term damage of diabetes to structures with a differentiated phenotype. There is a need to overcome major hurdles: (1) the ulcer is the consequence of the long-term damage of diabetes to skin tissue, nerves and vessels. (2) The architectural cells of granulation tissue are reluctant to proliferate and secrete, and become largely susceptible to apoptosis. Thus, the chronic phenotype is basically characterized by hypocellularity, deficient neomatrix synthesis-organization, cell cycle arrest and the onset of a senescent phenotype. Diabetes stamps some kind of metabolic memory as wound fibroblasts appear reluctant to proliferate even at optimal culture conditions. Understanding the mechanistic bases of this behavior could offer clues on the fundamentals of wound chronicity. Surgical debridement has always proved to be clinically useful. The former “chronic into the now acute” shift is the consequence of genes moved upon debridement that restore cells’ proliferative advantages. Moreover, a major clinical challenge is how to keep these wounds within a synchronous linear healing trajectory. It is likely that the administration of exogenous growth factors could become a fueling force.

As mentioned, diabetic ulcers show a huge failure in the physiology of the growth factors-receptors axis. The administration of natural or recombinant growth factors (single or combined) may be interpreted as a replacement therapy. It is likely that the therapeutic usefulness of growth factors stems from their ability to counter-balance a variety of cell-cycle inhibiting proteins that prevail in chronic wound G1-arrested cells.

The introduction of live skin equivalents have also shown clinical efficacy in the treatment of low-grade, neuropathic diabetic chronic wounds. They were found to significantly shorten healing time. These local bioreactors appear to nourish the wound cells with growth factors and ECM proteins that somehow ameliorate or prevent the deficient replication and proliferation that characterizes the diabetic wound milieu.

An important therapeutic area focuses on the down-regulation of the inflammatory process and its collateral effects. Thus far, the target has been TNF-α inhibition. The first evidence was provided by Doxycycline, an antibiotic that inhibits metalloproteinasas so as to TNF-α converting enzyme (TACE). Doxycycline improved the healing of chronic diabetic foot ulcers. The data was supported when using the therapeutic anti-TNF-α neutralizing antibody (infliximab) that was topically administered and improved the healing of a series of chronic ulcers of multi-factorial etiology. Irrespective of the differences existing in these studies, TNF-α neutralization is the common biological concept.

Novel and even more revolutionary therapeutic concepts are expected. Of particularly significance, and not only for wound healing, is the pharmacological manipulation of the AGE-RAGE axis. An intervention leading to the reduction of circulating and in-tissue accumulated AGE may even reach prophylactic value. On the same strategic line is the use of a decoy factor to prevent RAGE activation. The hypothesis that a soluble RAGE would restore healing progression was experimentally validated years ago. The manipulation of the AGE-RAGE axis may target more that one etiopathogenic damage component. The integrity and polyvalence of such an intervention would certainly contribute to improve healing in diabetic patients.

---


Received in July, 2010. Accepted for publication in September, 2010.